计算溶液所需的质量、体积或浓度。
CBT-295 is an orally active autotaxin ( ATX ) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β , TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy.